Therapeutic Advances in Neurological Disorders (Nov 2011)
Registries, research, and regrets: is the FDA’s post-marketing REMS process not adequately protecting patients?
Abstract
No abstracts available.
Therapeutic Advances in Neurological Disorders (Nov 2011)